Chidamide therapy to prevent relapse after stem cell transplant for t-cell leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a maintenance drug called chidamide, which may help keep your T-cell leukemia or lymphoma from returning after a stem cell transplant. You will take this drug as a pill to see if it extends the time you stay cancer-free.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have been diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
- You have already had a stem cell transplant using donor cells, and your cancer is in remission (no signs of active disease).
- You are generally in good health, with adequate heart, liver, and kidney function.
- You do not have severe graft-versus-host disease (GVHD) that is not controlled, or active serious infections.
- If you are of childbearing age, you must agree to use effective birth control during the study and for at least 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.